DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 00136]

Landmine Survivor Peer Support Networks in Five Mine-Affected Countries; Notice of Availability of Funds

A. Purpose

The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 2000 funds for a Cooperative Agreement Program for "Landmine Survivor Peer Support Networks in Five Mine-Affected Countries".

B. Eligible Applicant

Assistance will be provided only to Landmine Survivors Network (LSN). No other applications are solicited.

LSN is the most appropriate and qualified organization for conducting activities under this program because:

1. LSN has existing staff, both domestically and internationally, trained in public health and social sciences related to landmine survivors.
2. LSN has a significant global presence, allowing it to coordinate with local governments and international organizations in the implementation of projects related to landmine survivors.
3. LSN has a singularly high level of expertise and experience in working with landmine survivor issues.
4. LSN has an existing field presence including peer support networks in four of the five countries identified in this announcement (Bosnia, Ethiopia, Mozambique and Jordan).
5. LSN has established itself as a leader in the Non-Governmental Organization (NGO) community as a provider of support to individuals, families, and communities injured by landmines, giving it the resources and contacts to implement the program with the support of professional networks in the NGO community.

Note: Public Law 104–65 states that an organization described in section 501(c)(4) of the Internal Revenue Code of 1986 that engages in lobbying activities is not eligible to receive Federal funds constituting an award, grant, cooperative agreement, contract, loan, or any other form.

C. Availability of Funds

Approximately $1,200,000 is available in FY 2000 to fund this award. It is expected that the award will begin on or about September 30, 2000 and will be made for a 12-month budget period within a project period of up to 3 years.

D. Where To Obtain Additional Information

Program technical assistance may be obtained from: Brad Woodruff, International Emergency and Refugee Health Branch, National Center for Environmental Health, Centers for Disease Control and Prevention, 4770 Buford Highway, NE (F–48), Atlanta, GA 30341–3724, Telephone number: 770–488–3523, Email address: baw4@cdc.gov.

Business management technical assistance may be obtained from: Mattie Jackson, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention, Room 3000, 2920 Brandywine Road, Atlanta, GA 30341–4146, Telephone number: 770–488–2718, Email address: mj3@cdc.gov.

Dated: June 12, 2000.

John L. Williams,
Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

CDC Advisory Committee on HIV and STD Prevention: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: CDC Advisory Committee on HIV and STD Prevention.

Times and Dates:

8:30 a.m.–5 p.m., June 29, 2000.
8:30 a.m.–3 p.m., June 30, 2000.

Place: Marriott Atlanta Century Center, 2000 Century Boulevard NE, Atlanta, Georgia 30345.

Status: Open to the public, limited only by the space available. The meeting room will accommodate approximately 100 people.

Purpose: This Committee is charged with advising the Director, CDC, regarding objectives, strategies, and priorities for HIV and STD prevention efforts including maintaining surveillance of HIV infection, AIDS, and STDs, the epidemiologic and laboratory study of HIV/AIDS and STDs, information/education and risk reduction activities designed to prevent the spread of HIV and STDs, and other preventive measures that become available.

Matters To Be Discussed: Agenda items include issues pertaining to (1) national syphilis elimination efforts (2) strategic planning for HIV Prevention and (3) CDC’s HIV Prevention efforts in Africa and India.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information:
Paula Ford, Committee Management Analyst, National Center for HIV, STD, and TB Prevention, 1600 Clifton Road, NE, m/s E–07, Atlanta, Georgia 30333. Telephone 404/639–8008, fax 404/639–8600, e-mail pbfl@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: June 12, 2000.

John Burckhardt,
Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Notice]


AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a draft compliance policy guide (CPG) entitled “Apple Juice, Apple Juice Concentrates, and Apple Juice Products—Adulteration with...
Patulin. This document is intended to make FDA offices and industry aware of FDA’s guidance for enforcement concerning apple juice, apple juice concentrates, and apple juice products that contain patulin, a toxic substance produced by molds that may grow on apples, and that has been found to occur at high levels in some apple juice products offered for sale or import in the United States. The agency is also announcing the availability of a document entitled “Patulin in Apple Juice, Apple Juice Concentrates, and Apple Juice Products” (the draft supporting document).


ADDRESSES: Submit written requests for single copies of the draft CPG entitled “Apple Juice, Apple Juice Concentrates, and Apple Juice Containing Products—Adulteration with Patulin” and/or the draft supporting document entitled “Patulin in Apple Juice, Apple Juice Concentrates, and Apple Juice Products” to Michael E. Kashahtoc (address below). Send one self-addressed adhesive label to assist that office in processing your request. See the SUPPLEMENTARY INFORMATION section for electronic access to this document.

Submit written comments on the draft CPG and the draft supporting document to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Comments and requests for copies should be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Michael E. Kashahtoc, Center for Food Safety and Applied Nutrition (CFSAN) (HFS–305), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–205–5321, FAX 202–205–4422, e-mail: mkashahtoc@cfsan.fda.gov.

SUPPLEMENTARY INFORMATION: FDA has developed a draft CPG on FDA’s guidance for enforcement concerning apple juice, apple juice concentrates, and apple juice products that contain patulin. This document is intended to provide clear policy and regulatory guidance to FDA’s field and headquarters staff with regard to such foods. In particular, if these products: (1) Contain patulin at or above 50 parts per billion (ppb) (the action level) based on the level found or calculated to be found in single strength apple juice, reconstituted single strength apple juice (if the food is an apple juice concentrate), or the single strength apple juice component of the product (if the food contains apple juice as an ingredient); and (2) the identity of patulin is confirmed by gas chromatography/mass spectrometry, then the FDA field enforcement office may consider whether to recommend legal action against such apple juice, apple juice concentrates, and apple juice products in interstate commerce, and it may consider whether to recommend detention of the same products when offered for import into the United States. For the purposes of this guidance, single strength juice is 100 percent juice that is unconcentrated (see 21 CFR 101.30(h)). The scientific basis for the 50 ppb action level is presented in the draft supporting document. The draft CPG also contains information that may be useful to the regulated industry and to the public.

FDA has included an import specimen charge in this draft CPG to assist its field personnel in recommending refusal of admission for imported goods when warranted. The fact that this draft CPG contains an import specimen charge (in addition to the customary specimen charge addressing regulatory action against food in domestic commerce) does not restrict any action FDA may take under circumstances addressed by other CPG’s that do not have an import specimen charge, and it does not imply that FDA will not take action when warranted.

The agency has adopted good guidance practices (GGP’s) that set forth the agency’s policies and procedures for the development, issuance, and use of guidance documents (61 FR 8961, February 27, 1997). The draft CPG is being issued as a level 1 draft guidance consistent with GGP’s. The draft CPG represents the agency’s current thinking on its enforcement guidance concerning the adulteration of apple juice, apple juice concentrates, and apple juice products with patulin. It does not create or confer any rights for or on any person and does not operate to bind FDA, or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statute and regulations.

Interested persons may submit to the Dockets Management Branch (address above) written comments regarding the draft CPG and the draft supporting document by August 15, 2000. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments, the draft CPG and the draft supporting document may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday. These two documents may also be accessed at the CFSAN home page on the Internet at http://www.fda.cfsan.gov.

Dated: June 8, 2000.
Margaret M. Dotzel,
Associate Commissioner for Policy.
[FR Doc. 00–15122 Filed 6–15–00; 8:45 am]
BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Care Financing Administration

Privacy Act of 1974; Report of Altered Systems

AGENCY: Department of Health and Human Services (HHS), Health Care Financing Administration (HCFA).

ACTION: Notice of the modification or alteration to 20 systems of records.

SUMMARY: In accordance with the requirements of the Privacy Act of 1974, we are correcting information provided in 20 HCFA systems of records specified in Appendix A. These systems are all related to research or demonstration projects under the control of the Office of Strategic Planning. We are deleting the published routine uses in the system of records listed in Appendix A and replacing them with four revised routine uses. The routine uses are being prioritized and renumbered accordingly. We are taking the opportunity to update those sections of the SORS that were affected by the recent reorganization. We are also updating the language in the administrative sections to correspond with language used in other HCFA system of records.

The primary purpose of the corrections to these systems is to shorten the language, make the routine uses easier to read, and provide clarity to HCFA’s intention to disclose individual-specific information related to the purposes for which the information is being collected.

EFFECTIVE DATES: HCFA filed a correction to a system report with the Chair of the House Committee on Government Reform and Oversight, the Chair of the Senate Committee on Governmental Affairs, and the Administrator, Office of Information and Regulatory Affairs, Office of Management and Budget (OMB) on June 12, 2000. To ensure that all parties have adequate time in which to comment, the corrected systems of records, including routine uses, will become effective 40 days from the publication of the notice, or from the date it was submitted to OMB and the Congress, whichever is...